Reproduction permitted for personal use only. For reprints and reprint permission, contact email@example.com.
- Third Wave Technologies, Inc
., has reported a smaller net loss of $5.2 million, or 12 cents per share, thanks in part to higher clinical molecular diagnostic revenue during the third quarter of 2006.
Third Wave's net loss for the quarter compared favorably to a net loss of $7.4 million, or 18 cents per share, for the same period of 2005. With stock compensation costs factored in, the company's third-quarter net loss improved 37 percent from its pro forma net loss of $8.2 million, or 20 cents per share, for the same period of 2005.
The company reported clinical molecular diagnostic revenue of $5.4 million for the third quarter, an increase of 33 percent and six percent from the prior-year quarter and the previous quarter, respectively. In addition, Third Wave reported $1.2 million in research revenue during the third quarter, nearly all of which was generated by its Agbio business. Total revenues for the quarter were $6.6 million, an increase of more than 26 percent over the $5.2 million reported during the same period of 2005.
Clinical molecular diagnostic revenue for the nine-month period that ended Sept. 30 increased 33 percent to $15.1 million, compared to $11.4 million during the same period of 2005. Total revenue for the first nine months of 2006 increased 17 percent to $21.2 million, compared to $18.1 million in 2005.
Total operating expenses for the nine-month period were $36.5 million, compared to $36.0 million for the same period of 2005. With stock compensation costs included, Third Wave's pro forma total operating expenses totaled $40.0 million.
Third Wave ended the third quarter with cash, cash equivalents, and short-term investments of $33.0 million, compared to $38.7 million on Dec. 31, 2005.
For more details about the company's financial report and its latest stock price, visit (NASDAQ:TWTI
Third Wave reports another loss, stronger sales
Napier joins board of Third Wave Technologies
Third Wave's revenues rebound
Third Wave reports clinical growth, continued loss
Third Wave announces two senior management appointments